Skip to Content
Merck
All Photos(3)

Documents

453R-2

Sigma-Aldrich

p53 (EP9) Rabbit Monoclonal Primary Antibody

Sign Into View Organizational & Contract Pricing
All Photos(3)

About This Item

UNSPSC Code:
12352203
NACRES:
NA.41

biological source

rabbit

Quality Level

100
500

conjugate

unconjugated

antibody form

culture supernatant

antibody product type

primary antibodies

clone

EP9, monoclonal

description

For In Vitro Diagnostic Use in Select Regions (See Chart)

form

buffered aqueous solution

species reactivity

human

packaging

vial of 0.1 mL concentrate (453R-24)
vial of 0.1 mL concentrate Research Use Only (453R-24-RUO)
vial of 0.5 mL concentrate (453R-25)
bottle of 1.0 mL predilute ready-to-use (453R-27)
vial of 1.0 mL concentrate (453R-26)
vial of 1.0 mL concentrate Research Use Only (453R-26-RUO)
vial of 1.0 mL pre-dilute Research Use Only (453R-27-RUO)
bottle of 7.0 mL predilute ready-to-use (453R-28)
vial of 7.0 mL pre-dilute ready-to-use Research Use Only (453R-28-RUO)

manufacturer/tradename

Cell Marque™

technique(s)

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:100-1:200 (concentrate)

control

breast carcinoma ((breast ductal carcinoma in-situ)), colorectal carcinoma, ovarian carcinoma ((ovarian serous carcinoma)), urothelial carcinoma

shipped in

wet ice

storage temp.

2-8°C

visualization

nuclear

Gene Information

human ... TP53(7157)

Related Categories

General description

Anti-p53 tumor suppressor protein antibody recognizes a 53 kDa phosphoprotein, identified as p53 suppressor gene product. It reacts with the mutant as well as wild type p53, although significant accumulation of the mutant form of p53 protein due to longer half-life is the basis for the test using the IHC technique. Nuclear staining with this antibody has been shown in breast carcinoma, lung carcinoma, colorectal carcinoma, and urothelial carcinoma.

Quality

United States - IVD
Canada - IVD
European Union - IVD
Japan - RUO

Linkage

p53 Positive Control Slides, Product No. 453S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

Physical form

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

Preparation Note

Download the IFU specific to your product lot and format
Note: This requires a keycode which can be found on your packaging or product label.

Download the latest released IFU
Note: This IFU may not apply to your specific product lot

Other Notes

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Legal Information

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

12 - Non Combustible Liquids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

David J Dabbs et al.
The American journal of surgical pathology, 37(7), e1-11 (2013-06-14)
Lobular neoplasia (LN) is a term that encompasses both lobular carcinoma in situ and atypical lobular hyperplasia. These lesions have been shown to constitute both risk indicators and nonobligate precursors of invasive breast cancer, they are relatively uncommon, and are
J K McKenney et al.
The American journal of surgical pathology, 25(8), 1074-1078 (2001-07-28)
Distinction of urothelial carcinoma in situ (CIS) from reactive atypia on the basis of morphology alone may be difficult in some cases. Because this distinction is therapeutically and prognostically critical, we attempted to determine if an immunohistochemical panel would help
C Midulla et al.
Anticancer research, 19(5B), 4033-4037 (2000-01-11)
The different clinical evolution of breast cancer with similar pathological characteristics prompted the authors to investigate the prognostic significance of different biological markers. Seventy-one primary breast carcinoma specimens obtained by mastectomy or quadrantectomy were examined for the determination of the
F A Mauri et al.
International journal of oncology, 15(6), 1137-1147 (1999-11-24)
Steroid receptor analysis is the only widely accepted prognostic/predictive marker in breast cancer (BC) treatment. In the present study we evaluated the prognostic role of ER/PgR with p53 and Bcl2, in a series of 277 BC (153 pN1/2, 122 pNO
D C Quinlan et al.
Cancer research, 52(17), 4828-4831 (1992-09-01)
Mutations in the gene coding for the p53 tumor suppressor protein are common in a variety of human cancers. To assess the role of a putative mutated p53 protein in human lung cancer, a monoclonal antibody recognizing it was used
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service